| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA358: Tolvaptan for treating autosomal dominant polycystic kidney disease |
|
Medicine details |
|
| Medicine name | tolvaptan (Jinarc®) |
| Formulation | 15 mg, 30 mg, 45 mg, 60 mg and 90 mg tablet |
| Reference number | 568 |
| Indication | To slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adults with CKD stage 1 to 3 at initiation of treatment with evidence of rapidly progressing disease |
| Company | Otsuka Pharmaceutical (UK) Ltd |
| BNF chapter | Endocrine system |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 22/04/2015 |
| NICE guidance | TA358: Tolvaptan for treating autosomal dominant polycystic kidney disease |